^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
PM1080
i
Other names: PM1080, HS-20117
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
BioNTech, Jiangsu Hansoh Pharma
Drug class:
EGFR inhibitor, c-MET inhibitor
Related drugs:
6ms
A Phase Ib Study of HS-10504 Combined Therapy in NSCLC (clinicaltrials.gov)
P1, N=400, Not yet recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
New P1 trial
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
SHR-A2102 • PM1080 • ruzaltatug rezetecan (SHR-A2009)
1year
HS-20117 301: A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2/3, N=1080, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting
Enrollment open
|
Ameile (aumolertinib) • PM1080
over1year
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=762, Not yet recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
New P1 trial
|
cisplatin • carboplatin • 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium • AiRuiLi (adebrelimab) • HS-10370 • PM1080 • risvutatug rezetecan (GSK5764227)
over1year
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=780, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting
Enrollment open
|
BRAF (B-raf proto-oncogene)
|
cisplatin • carboplatin • 5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium • PM1080 • risvutatug rezetecan (GSK5764227)
almost2years
Phase Ib Trial of HS-20117 in Combination with Other Drugs in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=780, Not yet recruiting, Hansoh BioMedical R&D Company
New P1 trial
|
BRAF (B-raf proto-oncogene)
|
cisplatin • carboplatin • 5-fluorouracil • PM1080 • risvutatug rezetecan (GSK5764227)
2years
HS-20117 301: A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2/3, N=1080, Not yet recruiting, Hansoh BioMedical R&D Company
New P2/3 trial • Metastases
|
Ameile (aumolertinib) • PM1080
3years
A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=322, Not yet recruiting, Hansoh BioMedical R&D Company
New P1 trial • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
PM1080
Share via
